Nuvalent Inc Asset Resilience Ratio
Nuvalent Inc asset resilience ratio. Nuvalent Inc (NUVL) has an Asset Resilience Ratio of 84.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Nuvalent Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nuvalent Inc (2020–2025)
Asset resilience ratio of Nuvalent Inc from 2020 to 2025. This chart shows how Nuvalent Inc's Asset Resilience Ratio has changed over time. Read NUVL total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nuvalent Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Nuvalent Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.13 Billion | 84.72% |
| Total Liquid Assets | $1.13 Billion | 84.72% |
Asset Resilience Insights
- Very High Liquidity: Nuvalent Inc maintains exceptional liquid asset reserves at 84.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nuvalent Inc Industry Peers by Asset Resilience Ratio
Compare Nuvalent Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Nuvalent Inc Asset Resilience Ratio by Year (2020–2025)
Nuvalent Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Nuvalent Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.59% | $1.11 Billion | $1.41 Billion | -6.60pp |
| 2024-12-31 | 85.19% | $972.61 Million | $1.14 Billion | +32.68pp |
| 2023-12-31 | 52.50% | $384.52 Million | $732.38 Million | +4.76pp |
| 2022-12-31 | 47.75% | $230.36 Million | $482.46 Million | -26.99pp |
| 2021-12-31 | 74.73% | $219.59 Million | $293.82 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $10.65 Million | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more